# Dennis X. Hu

> Dennis X. Hu is the founder and CEO of Drug Hunter, a scientific information and intelligence platform. Trained at Northwestern, Cambridge and Stanford, he worked as a chemist and team leader at FLX Bio/RAPT Therapeutics and Genentech before taking Drug Hunter full-time in 2022. His public career combines research, education and the practical work of building an institutional subscription business.

- **Role:** Founder & CEO at Drug Hunter
- **Organizations:** Drug Hunter, Genentech, FLX Bio / RAPT Therapeutics
- **Education:** Dual BA/MS, Northwestern University, MPhil by Research in Chemistry; Churchill Scholar, University of Cambridge, PhD in Chemistry; adviser Noah Burns, Stanford University
- **Known for:** Goldwater Scholar, 2010., Churchill Scholar, 2011., Founded a program pairing local high school students with Northwestern student researchers.

## Career timeline

- **2010** — Awarded a Goldwater Scholarship at Northwestern.
- **2011** — Awarded a Churchill Scholarship for study at Cambridge.
- **2015** — Earned his Stanford chemistry PhD; began an industry career at FLX Bio/RAPT.
- **2018** — Started Drug Hunter alongside his scientific career.
- **2019-2022** — Worked in discovery chemistry at Genentech.
- **2022** — Announced full-time work on Drug Hunter in April.
- **2023** — Drug Hunter launched its homegrown platform and new commercial subscription plan.
- **2024** — May interview reported more than 150 institutional customers and ARR above $2 million.
- **2025** — September seed investment led by Teamworthy Ventures announced.
- **2026** — Listed as a plenary panel moderator for Discovery on Target.

## Achievements

- Goldwater Scholar, 2010.
- Churchill Scholar, 2011.
- Founded a program pairing local high school students with Northwestern student researchers.
- Coauthored scientific publications and patents across his academic and industry career.
- Built Drug Hunter into a platform relied on by researchers at more than 200 organizations, according to its September 2025 announcement.

## Latest updates

- **2026-09** — The Discovery on Target 2026 program listed Hu as a plenary panel moderator; the listing does not independently verify attendance.
- **2026-05** — Published commentary on AI tools, efficiency and the growing importance of scientists’ judgment.
- **2025-09** — Drug Hunter announced seed investment led by Teamworthy Ventures. Hu separately marked its thirtieth full-time team member.
- **2025-04** — Stanford listed an April 9 seminar with Hu.

## Links

- Website: https://drughunter.com/
- LinkedIn: https://www.linkedin.com/in/dennisxhu
- Twitter/X: https://x.com/DennisWhom

---

Profile page: https://yespress.io/dennis-x-hu
Published by YesPress — https://yespress.io
Last updated: 2026-10-11